RNA interference-induced innate immunity, off-target effect, or immune adjuvant?

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Meng, Zhongji ^a   Lu, Mengji ^b  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Immunostimulatory RNA; Immunostimulatory small interfering RNAs; Innate immunity; RNA interference; Small interfering RNA

Indexed keywords

ADJUVANT; DOUBLE STRANDED RNA; INTERFERON; SINGLE STRANDED RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

CYTOKINE PRODUCTION; DNA MODIFICATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC MANIPULATION; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; RNA STRUCTURE;

EID: 85017150258     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00331     Document Type: Review

References (57)

1. Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet (2001) 2:110-9. doi: 10.1038/35052556
2. Wang J, Mi P, Lin G, Wang YX, Liu G, Chen X. Imaging-guided delivery of RNAi for anticancer treatment. Adv Drug Deliv Rev (2016) 104:44-60. doi:10.1016/j.addr.2016.01.008
3. Landry B, Valencia-Serna J, Gul-Uludag H, Jiang X, Janowska-Wieczorek A, Brandwein J, et al. Progress in RNAi-mediated molecular therapy of acute and chronic myeloid leukemia. Mol Ther Nucleic Acids (2015) 4:e240. doi:10.1038/mtna.2015.13
4. Swamy MN, Wu H, Shankar P. Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. Adv Drug Deliv Rev (2016) 103:174-86. doi:10.1016/j.addr.2016.03.005
5. Gish RG, Satishchandran C, Young M, Pachuk C. RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study. Antivir Ther (2011) 16:547-54. doi:10.3851/IMP1798
6. DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A (2010) 107:8800-5. doi:10.1073/pnas.0912186107
7. Yuen M-F, Chan HLY, Liu K, Given BD, Schluep T, Hamilton J, et al. Differential reductions in viral antigens expressed from CCCDNA VS integrated DNA in treatment naïve HBEAG positive and negative patients with chronic HBV after RNA interference therapy with ARC-520. J Hepatol (2016) 64:S390-1. doi:10.1016/S0168-8278(16)00606-1
8. Marques JT, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol (2005) 23:1399-405. doi:10.1038/nbt1161
9. Sioud M. RNA interference and innate immunity. Adv Drug Deliv Rev (2007) 59:153-63. doi:10.1016/j.addr.2007.03.006
10. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther (2008) 19:991-9. doi:10.1089/hum.2008.131
11. Morral N, Witting SR. shRNA-induced interferon-stimulated gene analysis. Methods Mol Biol (2012) 820:163-77. doi:10.1007/978-1-61779-439-1_10
12. Olejniczak M, Polak K, Galka-Marciniak P, Krzyzosiak WJ. Recent advances in understanding of the immunological off-target effects of siRNA. Curr Gene Ther (2011) 11:532-43. doi:10.2174/156652311798192770
13. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 5:834-9. doi:10.1038/ncb1038
14. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 34:263-4. doi:10.1038/ng1173
15. Olejniczak M, Galka-Marciniak P, Polak K, Fligier A, Krzyzosiak WJ. RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents. RNA (2012) 18:930-5. doi:10.1261/rna.025627.110
16. Meng Z, Qiu S, Zhang X, Wu J, Schreiter T, Xu Y, et al. Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression. Virology (2009) 384:88-96. doi:10.1016/j.virol.2008.11.012
17. Meng Z, Zhang X, Wu J, Pei R, Xu Y, Yang D, et al. RNAi induces innate immunity through multiple cellular signaling pathways. PLoS One (2013) 8:e64708. doi:10.1371/journal.pone.0064708
18. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science (2006) 314:997-1001. doi:10.1126/science.1132998
19. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med (2008) 205:1601-10. doi:10.1084/jem.20080091
20. Malathi K, Dong B, Gale MJ, Silverman RH. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature (2007) 448:816-9. doi:10.1038/nature06042
21. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology (2006) 130:1886-900. doi:10.1053/j.gastro.2006.01.038
22. Li S, Peters GA, Ding K, Zhang X, Qin J, Sen GC. Molecular basis for PKR activation by PACT or dsRNA. Proc Natl Acad Sci U S A (2006) 103:10005-10. doi:10.1073/pnas.0602317103
23. Sadler AJ, Williams BR. Structure and function of the protein kinase R. Curr Top Microbiol Immunol (2007) 316:253-92. doi:10.1007/978-3-540-71329-6_13
24. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol (2005) 348:1079-90. doi:10.1016/j.jmb.2005.03.013
25. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 11:263-70. doi:10.1038/nm1191
26. Cekaite L, Furset G, Hovig E, Sioud M. Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol (2007) 365:90-108. doi:10.1016/j.jmb.2006.09.034
27. Forsbach A, Nemorin JG, Montino C, Muller C, Samulowitz U, Vicari AP, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol (2008) 180:3729-38. doi:10.4049/jimmunol.180.6.3729
28. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 23:457-62. doi:10.1038/nbt1081
29. Lin X, Ruan X, Anderson MG, McDowell JA, Kroeger PE, Fesik SW, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res (2005) 33:4527-35. doi:10.1093/nar/gki762
30. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis ESC. Nucleic acid agonists for toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol (2006) 36:3256-67. doi:10.1002/eji.200636617
31. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol (2006) 36:1222-30. doi:10.1002/eji.200535708
32. Gantier MP, Tong S, Behlke MA, Xu D, Phipps S, Foster PS, et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol (2008) 180:2117-24. doi:10.4049/jimmunol.180.4.2117
33. Kabilova TO, Meschaninova MI, Venyaminova AG, Nikolin VP, Zenkova MA, Vlassov VV, et al. Short double-stranded RNA with immunostimulatory activity: sequence dependence. Nucleic Acid Ther (2012) 22:196-204. doi:10.1089/nat.2011.0328
34. Marques JT, Devosse T, Wang D, Zamanian-Daryoush M, Serbinowski P, Hartmann R, et al. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol (2006) 24:559-65. doi:10.1038/nbt1205
35. Pebernard S, Iggo RD. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation (2004) 72:103-11. doi:10.1111/j.1432-0436.2004.07202001.x
36. Ebert G, Poeck H, Lucifora J, Baschuk N, Esser K, Esposito I, et al. 5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology (2011) 141:706.e1-3. doi:10.1053/j.gastro.2011.05.001
37. Han Q, Zhang C, Zhang J, Tian Z. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology (2011) 54:1179-89. doi:10.1002/hep.24505
38. Chen X, Qian Y, Yan F, Tu J, Yang X, Xing Y, et al. 5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells. Eur J Pharmacol (2013) 721:86-95. doi:10.1016/j.ejphar.2013.09.050
39. Gantier MP, Tong S, Behlke MA, Irving AT, Lappas M, Nilsson UW, et al. Rational design of immunostimulatory siRNAs. Mol Ther (2010) 18:785-95. doi:10.1038/mt.2010.4
40. Fish RJ, Kruithof EK. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol (2004) 5:9. doi:10.1186/1471-2199-5-9
41. Moschos SA, Jones SW, Perry MM, Williams AE, Erjefalt JS, Turner JJ, et al. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem (2007) 18:1450-9. doi:10.1021/bc070077d
42. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 23:1002-7. doi:10.1038/nbt1122
43. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 314:994-7. doi:10.1126/science.1132505
44. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity (2005) 23:165-75. doi:10.1016/j.immuni.2005.06.008
45. Broering R, Real CI, John MJ, Jahn-Hofmann K, Ickenstein LM, Kleinehr K, et al. Chemical modifications on siRNAs avoid toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. Int Immunol (2014) 26:35-46. doi:10.1093/intimm/dxt040
46. Hoerter JA, Walter NG. Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA (2007) 13:1887-93. doi:10.1261/rna.602307
47. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther (2006) 13:494-505. doi:10.1016/j.ymthe.2005.11.002
48. Flatekval GF, Sioud M. Modulation of dendritic cell maturation and function with mono-and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase. Immunology (2009) 128:e837-48. doi:10.1111/j.1365-2567.2009.03093.x
49. Bell JK, Askins J, Hall PR, Davies DR, Segal DM. The dsRNA binding site of human toll-like receptor 3. Proc Natl Acad Sci U S A (2006) 103:8792-7. doi:10.1073/pnas.0603245103
50. Sioud M. Overcoming the challenges of siRNA activation of innate immunity: design better therapeutic siRNAs. Methods Mol Biol (2015) 1218:301-19. doi:10.1007/978-1-4939-1538-5_19
51. Furset G, Floisand Y, Sioud M. Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to toll-like receptor-7/8 ligands. Immunology (2008) 123:263-71. doi:10.1111/j.1365-2567.2007.02695.x
52. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 15:1663-9. doi:10.1038/sj.mt.6300240
53. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol (2005) 77:3-15. doi:10.1189/jlb.0904484
54. Sioud M, Saeboe-Larssen S, Hetland TE, Kaern J, Mobergslien A, Kvalheim G. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients. Int J Oncol (2013) 43:280-8. doi:10.3892/ijo.2013.1922
55. Joshi G, Dash PK, Agarwal A, Sharma S, Parida M. Bifunctional siRNA containing immunostimulatory motif enhances protection against pandemic H1N1 virus infection. Curr Gene Ther (2015) 15:492-502. doi:10.2174/1566523215666150812120547
56. Wang K, Chen X, Yan F, Xing Y, Yang X, Tu J, et al. 5'-triphosphate-siRNA against survivin gene induces interferon production and inhibits proliferation of lung cancer cells in vitro. J Immunother (2013) 36:294-304. doi:10.1097/CJI.0b013e318294183b
57. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 14:1256-63. doi:10.1038/nm.1887